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Objectives: Over the last decades, there has been a significant increase in antimicrobial prescribing and
consumption associated with the development of patients’ adverse events and antimicrobial resistance (AMR)
to the point of becoming a global priority. This study aims at evaluating antibiotic prescribing during COVID-
19 pandemic from November 2019 to December 2020.
Materials and Methods: A systematic review was conducted primarily through the NCBI database, using
PRISMA guidelines to identify relevant literature for the period between November 1, 2019 and December 19,
2020, using the keywords: COVID-19 OR SARS-Cov-2 AND antibiotics restricted to the English language
excluding nonclinical articles. Five hundred twenty-seven titles were identified; all articles fulfilling the study
criteria were included, 133 through the NCBI, and 8 through Google Scholar with a combined total of 141
studies. The patient’s spectrum included all ages from neonates to elderly with all associated comorbidities,
including immune suppression.
Results: Of 28,093 patients included in the combined studies, 58.7% received antibiotics (16,490/28,093),
ranging from 1.3% to 100% coverage. Antibiotics coverage was less in children (57%) than in adults with
comorbidities (75%). Broad-spectrum antibiotics were prescribed presumptively without pathogen identifica-
tions, which might contribute to adverse outcomes.
Conclusions: During the COVID-19 pandemic, there has been a significant and wide range of antibiotic
prescribing in patients affected by the disease, particularly in adults with underlying comorbidities, despite the
paucity of evidence of associated bacterial infections. The current practice might increase patients’ immediate
and long-term risks of adverse events, susceptibility to secondary infections as well as aggravating AMR.
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Introduction
The discovery of antibiotics in the middle of the 20thcentury was a significant breakthrough for humanity
saving millions of lives and preventing significant morbidity
and mortality associated with infectious diseases.1 A decade
after the historical discovery, a noticeable antimicrobial
resistance (AMR) was observed escalating to an alarming
scale over recent years.2 It has been estimated that about
700,000 annual global mortality is attributed to AMR, which
attracted the attention of world leaders and international
organizations such as the World Health Organization
(WHO) all advocating regional and global initiatives to
contain the problem.3 Antimicrobial Stewardship Programs
(ASPs) have been implemented in many health care settings
worldwide to curtail inappropriate and excessive antibiotic
prescribing, particularly for broad-spectrum antibiotics.4 At
the end of 2019, the world witnessed a worrying herald of a
global pandemic caused by a novel coronavirus coined
SAR-CoV-2 leading to the clinical syndrome of COVID-19
disease.5 Although the disease causes a respiratory illness
primarily, it was noticed from the beginning it is associated
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with significant secondary presentations, including multisys-
tem complications in need of critical care, particularly for
server disease. Since there was no available effective man-
agement, antibiotics were frequently prescribed for various
rationales with the potential of contributing to AMR.6 Al-
though COVID-19 principally is a viral infection not usually
responding to antibiotics, it is capable of causing an acute
respiratory disease indistinguishable from bacterial infections
and creating an environment and complications favoring
secondary bacterial infections.7 For such reasons, health care
professionals were confounded to prescribe antibiotics to treat
potential bacterial infections or secondary complications. To
comprehend the scale of the problem, a study conducted by
the WHO demonstrated that 72% of COVID-19 patients re-
ceived antibiotics. Nevertheless, only 8% had evidence of
documented superimposed bacterial infections.8
To add to the complexity of the situation, unverified
research at the start of the pandemic advocated combined
management with chloroquine/hydroxychloroquine together
with the macrolide antibiotic azithromycin led to hasty in-
clusion in many COVID-19 management guidelines across
the globe before establishing better-evaluated efficacy.9
Even for patients who warrant treatment during the pan-
demic, Getahun et al.8 indicated that antimicrobials were
overprescribed for patients admitted to intensive care
units (ICUs) in 88 countries where 70% of patients re-
ceived antibiotics. However, only 54% of patients had sus-
pected or proven bacterial infections. Because of the gravity
of the situation, confusion of the optimal management
approaches for the novel disease together with the stretch-
ing of physical limits and capabilities of health care ASPs;
the COVID-19 pandemic created an environment for inap-
propriate and excessive antibiotic prescribing, which might
worsen future AMR through selective pressures. The pre-
sented literature review is conducted to examine and high-
light the spectrum of antimicrobial prescribing during the
COVID-19 pandemic to raise awareness toward potential
consequences.
Materials and Methods
A literature search was conducted using the PRISMA
guidelines for systematic reviews.172 The NCBI database
was identified as a primary source of related literature be-
cause of clinical relevance between November 2019 and
December 19, 2020. Adopted search keywords were
COVID-19 OR Sars-Cov-2 AND antibiotics restricted to the
English language. The search initially resulted in 527
identified titles eventually limited to 133 following applying
restrictive criteria. An additional 8 articles were included
following searching Google Scholar search engine, bringing
the total number to 141 studies. As per the study protocol,
only articles covering clinical settings were included,
articles limited to basic science, solely microbiological
characteristics, experiments, surveys, guidelines, and hy-
potheses. Those not providing details of antibiotic pre-
scribing were excluded (n = 386) (Fig. 1). The information
extracted from the included articles comprises types of an-
tibiotics prescribed for COVID-19 patients and the number
of those patients, bacterial coinfection, and relevant patient
demographic data (age, gender, and country). In addition, if
the COVID-19 patient is suffering from any other compli-
cations such as hypertension, cardiac disease, diabetes,
pregnancy, cancer, and human immunodeficiency virus
(HIV) were reported.
Results
One hundred forty-one articles were included in this re-
view from 28 different countries. The majority of them are
from countries worst affected by the pandemic: China
(n = 55), followed by the USA (n = 18), Italy (n = 10), UK
(n = 5), Spain (n = 5), Brazil (n = 4), Iran (n = 4), and India
(n = 3). Two articles were incorporated from Belgium,
Germany, Japan, South Korea, Netherlands, and Saudi
Arabia and one from Bhutan, Colombia, France, Ireland,
Morocco, Niger, Oman, Philippines, Qatar, Singapore,
Switzerland, Taiwan, and Uganda. Fourteen articles were
included with no identified country (Table 1).
The study population’s demographic and clinical char-
acteristics included all ages from neonates, children, and
adults, including pregnant women and the elderly. Asso-
ciated underlying conditions included hypertension, diabetes
mellitus, heart, respiratory, renal, liver, thyroid, cerebro-
vascular, rheumatic diseases, and HIV and organ trans-
plantation (heart, lung, kidney, liver, and bone marrow). Of
28,093 patients included in the combined studies, 58.7%
received antibiotics (16,490/28,093). The percentage of
patients prescribed antibiotics in each article differs, ranging
from 1.3% to 100% coverage, with only 9.9% of the articles
reporting less than 50% antibiotic covering (14/141). Most
included articles did not present clear data on an antibiotic
prescription for patients with other complications versus
those without comorbidities. Comparing the articles that
include the population who suffered from other diseases to
those with no other complications, we found that antibiotic
coverage did not differ significantly between patients with
and without comorbidities (75.2%, 415/552), and 71%
(8,449/11,886), respectively (Fig. 2).
Antibiotics coverage was less in children, 57% (187/329)
compared to adults, and it was least in pregnant women
(34.5%, 29/84). Despite the high percentage of antibiotic
prescribing, most articles did not report bacterial coinfection
(75.36%), indicating that probably a significant amount of
antibiotics were empirically and unnecessarily prescribed.
The spectrum of antimicrobial prescreening is broad since
more than 40 different antimicrobials were used to manage
patients with COVID-19 disease (Table 2).
Inferring from the number of articles reporting the use of
specific antibiotics, cephalosporins followed by azi-
thromycin and moxifloxacin were the predominant oral
antibiotics while piperacillin/tazobactam was the prevalent
parenteral antibiotic. However, when subdividing cephalo-
sporins into distinct classes based on their generation (first
vs. second vs. third vs. fourth), azithromycin becomes the
predominant antibiotic reported, which reflects its prominent
role during the pandemic. Nevertheless, most studies high-
lighted that the majority of antibiotics were prescribed
empirically as prophylaxis to prevent secondary bacterial
infection,70 to treat secondary bacterial infection such as
pneumonia,59 or as potential COVID-19 treatment agents.53
Other described drugs reported include meropenem, levo-
floxacin, linezolid, vancomycin, amoxicillin/clavulanate,
Teicoplanin, and carbapenem.
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Discussion
The excessive and inappropriate prescribing of antibiotics
is a significant challenge for health care across the globe.
The escalating problem has been directly associated with
detrimental patients’ safety through the development of di-
rect adverse events, indirect acquisition of secondary health
care-associated infections, propagation of AMR, worsening
infection control and prevention measures, as well as sub-
stantial cost implications.148,149 Of all infectious diseases,
respiratory infections are the leading cause of inappropriate
antibiotic prescribing and overuse. The majority of upper
respiratory tract infections are caused by viruses, and only
less than 10% are caused by bacteria150; nevertheless, the
WHO reported that in 2016, 71% of patients with UTRIs
had been prescribed antibiotics.151
The COVID-19 pandemic caught all health care settings
across the globe by surprise; the novel SARS-CoV-2 virus
caused an unprecedented universal health scare since there
was little preceding knowledge about the disease and its
implications, particularly potential secondary infections.
Furthermore, the disease presents primarily as a respiratory
illness mimicking bacterial infections hence confounding
clinical assessment; conversely, critical patients need in-
vasive procedures often associated with secondary health
care-associated infections. To add the disease complexity,
unverified early clinical reports and trials advocated using
antibiotics to hinder disease progression and hasten viral
clearance, despite the discouragement of such an approach
by international guidelines.8 Consequent to all these factors,
antibiotic prescribing was noticeably frequent in patients
with COVID-19 disease.
FIG. 1. Schematic selection process of included studies.























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Our search encompassed about 28,000 patients from 28
different countries, to evaluate the problem systematically,
the majority of which were severely affected by the pan-
demic, such as China, Iran, Italy, Spain, UK, and the USA,
demonstrated widespread practice of prescribing antibiotics
particularly in adults underlying clinical with conditions.
The overall percentage of cases prescribed antimicrobial
therapy is evident in 58.7% of cases being more com-
mon with premorbid or immune-compromised conditions
(Fig. 1). Several authors reported treatment strategies for
COVID-19 patients incorporating empirical antibiotic
treatment.14,30,37,58,152 Such observations are in line with
early pandemic epidemiological reports since it was appar-
ent that more severe and critical disease is predominant
in the elderly and those with underlying premorbid condi-
tions such as diabetes, heart failure, and the immune-
compromised. Conversely, severity markers included acute
kidney and liver injuries, explaining antibiotic prescribing
prevalence in such populations.
It is worth noticing; prescribed antibiotics are not nec-
essarily to cover documented secondary bacterial infections
since, in many studies, the presence of bacterial coinfection
or secondary infection is much lower than the number of
patients prescribed antimicrobial therapy. In their review,
Lai et al.153 reviewed 13 papers for the presence of bacterial
coinfection or secondary infection, 5 of which reported 0%
bacterial coinfection or secondary infection. In contrast,
three reported a low percentage of 1%, 3.4%, and 4.8%,
respectively. Similarly, a large-scale study from New York
described 5,700 patients with only 3 secondary bacterial
infections.154 On the contrary, this in contrast with Italy’s
study, where 17.2% of patients had bacterial pneumonia and
37% suffered from secondary bacteremia.155 Lansbury et al.
covered 30 studies and 3,834 patients, demonstrating only
7% of the hospitalized patients infected with COVID-19 had
a bacterial coinfection.156 Understandably, the presence of
bacterial coinfection was highest in ICU patients (14%)
compared to patients in mixed wards (4%). A third review
reported 8% of bacterial or fungal coinfection.7
The reviewed evidence supports the discrepancy between
inappropriate and excessive antibiotic prescribing in patients
with COVID-19 disease and the presence of bacterial co-
infections. Nevertheless, Chien-Yi Chang and Kok-Gan
Chan argue that the low rate of coinfection could result from
prescribing antibiotics on a large scale to avoid over-
whelming health systems during the early pandemic.157
Furthermore, some have argued that the lack of clear anti-
microbial stewardship guidance for the frontline clinician at
the early stages of the pandemic probably resulted in an
inclination toward antimicrobial prescribing, especially in
the early stages of the pandemic. In addition, Lansbury
et al.’s156 analysis shows that more than 90% of the patients
in 10 out of 17 studies, in which patients were prescribed
antibiotics, received the antimicrobial therapy empirically.
It is also worth mentioning that in patients with moderate
and severe symptoms, those who received antibiotics or
corticosteroids had more extended hospital stays than those
who did not.17
It is worth noting that the high percentage of antibiotic
prescribing in patients with no comorbidities (71%) could be
confounded by not reporting them in some of the articles,
which does not equate to their absence. It is quite possible
that an undetermined percentage of patients in such studies
suffer from comorbidities. The review also demonstrated
lower antibiotic prescribing patterns in the pediatrics pop-
ulation; from 329 neonates, infants, and children included in
the review, only 187 (57%) were prescribed antimicrobial
therapy. This is a lower rate but might also be appropriate
since coinfection is expected in the pediatric population
since two studies reported 40% and 51.3% coinfection rates,
respectively.158,159 This indicates that the pediatric popula-
tion might have been better managed during the pandemic
from the ASP point of view. Pregnant women were the least
to be prescribed antimicrobial therapy, with only 34.5%,
which might be due to fears of prescribing antimicrobials
during pregnancy rather than its liberal use when compared
to a similar cohort, however, we are not sure of the reason
for this lower rate in antimicrobial prescription in pregnant
women.
The macrolide antibiotic azithromycin was the predomi-
nant antimicrobial agents reported in the management of
COVID-19 disease (Table 2). Most possible, it was used for
FIG. 2. Comparison of
percentage antibiotic pre-
scription in studied popula-
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its claimed anti-inflammatory effect.160 Before the start of
the pandemic, it was used mostly to treat community-
acquired pneumonia as well as exacerbations of chronic
obstructive pulmonary disease.161 Azithromycin’s role has
been recognized by previous reports of efficacy against other
RNA viruses such as Zika and Ebola virus disease162–164 and
has been speared when suggested as an adjunct to hydro-
xychloroquine leading to rapid viral clearance in COVID-19
patients through unclear mechanisms.9 This probably reflects
the highlighted issue with the drug in the foremost pandemic
history.160 Although some limited reports support improved
outcomes with adjunctive macrolides in the treatment of
COVID-19 disease stemming from previous observations of
moderate-to-severe acute respiratory distress syndrome, this
has not been materialized in COVID-19 clinical trials.165
Furthermore, both hydroxychloroquine/chloroquine and azi-
thromycin have been associated with cardiotoxicity by
prolonging the QT intervals (the time it takes for the ven-
tricles of the heart to contract and relax), which might pre-
cipitate arrhythmias in susceptible patients, particularly those
with cardiac diseases, the impact of which is yet to be
thoroughly evaluated.166 The widely used antibiotic azi-
thromycin was gradually recognized as a rare cause of pro-
longed QT, severe arrhythmia, and increased risk of sudden
death.167–170 Beović et al.171 reported that broad-spectrum
antibiotic use in patients with COVID-19 is widespread,
according to his survey study administered across 82 hos-
pitals in 23 countries. Importantly, different broad-spectrum
antibiotics have been frequently prescribed, including pi-
peracillin/tazobactam, meropenem, vancomycin, and teico-
planin, highlighting potential further development of current
or future AMR. More than half of the respondents reported
combined use of b-lactams and macrolides or fluor-
oquinolones, and the most commonly prescribed antibiotic in
the COVID-19 ICU was piperacillin/tazobactam.171 Worry-
ingly, most broad-spectrum antibiotics have been prescribed
empirically as prophylaxis to prevent secondary bacterial
infection,70 or to treat bacterial secondary infection and
pneumonia,59 or as part of COVID-19 treatment53
Although the systematic search captured a significant
number of studies in a short time frame, we acknowledge
there are some accompanying limitations. Restricting in-
clusion to the English language probably omitted other
thematic studies. The pandemic’s dynamic nature and short
time reporting scope probably caused reporting bias, which
might be corrected over time. Nevertheless, our report
outcomes are in line with other conducted cross-sectional
studies such as the WHO studied report.8
In summary, this systematic review demonstrated the
widespread practice of antibiotic prescribing for COVID-19
patients during the pandemic with little supporting evidence
of secondary bacterial infections. While the practice is more
frequent in adult patients with comorbidities than in the
younger population, this might reflect more advanced and
severe diseases in this population. We encourage the ap-
propriate and judicious use of antimicrobials, particularly
broad-spectrum antibiotics, to avoid short- and long-term
consequences. We anticipate if no appropriate actions have
been taken throughout the pandemic through various ele-
ments of ASPs or tailored COVID-19 management guide-
lines, such practice might become an established culture
with all its detrimental consequences.
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